DK1053017T3 - Vacciner omfattende interleukin-12 og herpes simplex virusantigen - Google Patents

Vacciner omfattende interleukin-12 og herpes simplex virusantigen

Info

Publication number
DK1053017T3
DK1053017T3 DK99905946T DK99905946T DK1053017T3 DK 1053017 T3 DK1053017 T3 DK 1053017T3 DK 99905946 T DK99905946 T DK 99905946T DK 99905946 T DK99905946 T DK 99905946T DK 1053017 T3 DK1053017 T3 DK 1053017T3
Authority
DK
Denmark
Prior art keywords
interleukin
herpes simplex
simplex virus
vaccines
virus antigen
Prior art date
Application number
DK99905946T
Other languages
Danish (da)
English (en)
Inventor
Eric M Mishkin
John H Eldridge
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1053017T3 publication Critical patent/DK1053017T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK99905946T 1998-02-12 1999-02-10 Vacciner omfattende interleukin-12 og herpes simplex virusantigen DK1053017T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
EP19990905946 EP1053017B1 (en) 1998-02-12 1999-02-10 Vaccines comprising interleukin-12 and herpes simplex viral antigen

Publications (1)

Publication Number Publication Date
DK1053017T3 true DK1053017T3 (da) 2004-11-22

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99905946T DK1053017T3 (da) 1998-02-12 1999-02-10 Vacciner omfattende interleukin-12 og herpes simplex virusantigen

Country Status (15)

Country Link
US (1) US6488936B1 (enExample)
EP (1) EP1053017B1 (enExample)
JP (1) JP2002502884A (enExample)
KR (1) KR100622716B1 (enExample)
CN (1) CN1224422C (enExample)
AT (1) ATE275421T1 (enExample)
AU (1) AU764036B2 (enExample)
BR (1) BR9907883A (enExample)
CA (1) CA2320041A1 (enExample)
DE (1) DE69919984T2 (enExample)
DK (1) DK1053017T3 (enExample)
ES (1) ES2226338T3 (enExample)
IL (1) IL137811A (enExample)
PT (1) PT1053017E (enExample)
WO (1) WO1999040938A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013916A3 (cs) 1999-05-13 2002-06-12 American Cyanamid Company Adjuvantní kombinované prostředky
ATE319833T1 (de) * 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒－2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
US8729058B2 (en) * 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA3023446A1 (en) 2016-05-10 2017-11-16 Hennepin Healthcare Research Institute Cytokine signaling immunomodulators and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
KR20010040867A (ko) 2001-05-15
EP1053017A2 (en) 2000-11-22
JP2002502884A (ja) 2002-01-29
CA2320041A1 (en) 1999-08-19
WO1999040938A2 (en) 1999-08-19
KR100622716B1 (ko) 2006-09-13
IL137811A0 (en) 2001-10-31
BR9907883A (pt) 2000-11-14
AU2598199A (en) 1999-08-30
ES2226338T3 (es) 2005-03-16
PT1053017E (pt) 2004-12-31
WO1999040938A3 (en) 2000-08-24
IL137811A (en) 2005-12-18
AU764036B2 (en) 2003-08-07
EP1053017B1 (en) 2004-09-08
US6488936B1 (en) 2002-12-03
CN1299287A (zh) 2001-06-13
DE69919984T2 (de) 2005-11-17
DE69919984D1 (de) 2004-10-14
CN1224422C (zh) 2005-10-26
ATE275421T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DK1053017T3 (da) Vacciner omfattende interleukin-12 og herpes simplex virusantigen
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
FR20C1016I1 (enExample)
ES2186809T3 (es) Composiciones de vacunas para administracion intranasal, comprendiendo chitosana y su uso.
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
EP1032417A4 (en) BACTERIAL VACCINES CONTAINING ATTENUATED AUXOTROPHIC STRAINS OF LISTERIA EXPRESSING HETEROLOGIC ANTIGENS
MX9702336A (es) Composiciones de vacuna.
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2002062296A3 (en) Methods and compositions useful for stimulating an immune response
DK1047446T3 (da) Vaccinesammensætning til Herpes Simplex virus og fremgangsmåder til anvendelser deraf
DK0939648T3 (da) Rotavirusvaccineformuleringer
WO2005012538A3 (en) Accelerated vaccination
GB9818133D0 (en) Vaccine
WO1999040937A3 (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
AU8467201A (en) Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
EP1027895A3 (en) Erysipelothrix rhusiopathiae antigens and vaccine compositions